PTGS2 and fatty liver disease: Thus, both the knockdown of type IV phospholipase A26,7, which releases arachidonic acid for prostaglandin synthesis from phospholipids, or a selective inhibition of cyclooxygenase 2 (COX-2)8, the key enzyme in prostaglandin synthesis, protected against diet-induced hepatic steatosis.